JP2023523130A5 - - Google Patents

Info

Publication number
JP2023523130A5
JP2023523130A5 JP2022554565A JP2022554565A JP2023523130A5 JP 2023523130 A5 JP2023523130 A5 JP 2023523130A5 JP 2022554565 A JP2022554565 A JP 2022554565A JP 2022554565 A JP2022554565 A JP 2022554565A JP 2023523130 A5 JP2023523130 A5 JP 2023523130A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
independently
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022554565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523130A (ja
JP7681038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/090898 external-priority patent/WO2021219070A1/en
Publication of JP2023523130A publication Critical patent/JP2023523130A/ja
Publication of JP2023523130A5 publication Critical patent/JP2023523130A5/ja
Priority to JP2025078734A priority Critical patent/JP2025122005A/ja
Application granted granted Critical
Publication of JP7681038B2 publication Critical patent/JP7681038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022554565A 2020-04-30 2021-04-29 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 Active JP7681038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078734A JP2025122005A (ja) 2020-04-30 2025-05-09 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088322 2020-04-30
CN2020088322 2020-04-30
CN2021085369 2021-04-02
CNPCT/CN2021/085369 2021-04-02
PCT/CN2021/090898 WO2021219070A1 (en) 2020-04-30 2021-04-29 Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078734A Division JP2025122005A (ja) 2020-04-30 2025-05-09 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法

Publications (3)

Publication Number Publication Date
JP2023523130A JP2023523130A (ja) 2023-06-02
JP2023523130A5 true JP2023523130A5 (cg-RX-API-DMAC7.html) 2024-05-09
JP7681038B2 JP7681038B2 (ja) 2025-05-21

Family

ID=78374077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554565A Active JP7681038B2 (ja) 2020-04-30 2021-04-29 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法
JP2025078734A Pending JP2025122005A (ja) 2020-04-30 2025-05-09 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078734A Pending JP2025122005A (ja) 2020-04-30 2025-05-09 Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法

Country Status (12)

Country Link
US (1) US20230167118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146655A4 (cg-RX-API-DMAC7.html)
JP (2) JP7681038B2 (cg-RX-API-DMAC7.html)
CN (4) CN116589466B (cg-RX-API-DMAC7.html)
AU (1) AU2021264916B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019014A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172498A1 (cg-RX-API-DMAC7.html)
IL (1) IL297664A (cg-RX-API-DMAC7.html)
MX (1) MX2022013407A (cg-RX-API-DMAC7.html)
TW (2) TWI902789B (cg-RX-API-DMAC7.html)
WO (1) WO2021219070A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209962B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146655A4 (en) * 2020-04-30 2024-07-31 BeiGene, Ltd. DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE
US20240246977A1 (en) * 2020-12-31 2024-07-25 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
US20240287076A1 (en) * 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
AU2022300033A1 (en) * 2021-06-21 2024-01-18 Beone Medicines I Gmbh (r) -glutarimide crbn ligands and methods of use
CN119823111B (zh) * 2021-11-18 2026-05-05 正大天晴药业集团股份有限公司 稠合酰亚胺类衍生物
CN118414336A (zh) * 2021-12-30 2024-07-30 百济神州有限公司 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法
CA3240051A1 (en) * 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
CN118946561A (zh) * 2023-03-10 2024-11-12 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途
WO2025168081A1 (en) * 2024-02-09 2025-08-14 Beigene (Suzhou) Co., Ltd. Treating b-cell proliferative disorder with chimeric degradation activating compound
CN120623148A (zh) * 2024-03-11 2025-09-12 北京深势科技有限公司 一种c-Myc降解剂及其制备方法和用途
TW202543648A (zh) * 2024-04-19 2025-11-16 瑞士商百濟神州瑞士有限責任公司 包含布魯頓氏酪胺酸激酶降解劑之固體形式及其用途
WO2025232885A1 (en) * 2024-05-10 2025-11-13 Beigene (Suzhou) Co., Ltd. Preparation method of a bruton's tyrosine kinase degrader thereof
TW202610637A (zh) * 2024-07-10 2026-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種雜芳基類化合物、其製備方法及其在醫藥上的應用
WO2026021570A1 (en) * 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof
US20260028345A1 (en) 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof
WO2026119195A1 (en) 2024-12-04 2026-06-11 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising amorphous solid dispersion of bruton's tyrosin kinase degrader
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026153355A1 (zh) * 2025-01-14 2026-07-23 江苏恒瑞医药股份有限公司 一种杂芳基类化合物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
BR112015007513A2 (pt) * 2012-10-26 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN111936501B (zh) * 2018-03-26 2023-09-22 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
EP3774804A1 (en) * 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
EP4146655A4 (en) * 2020-04-30 2024-07-31 BeiGene, Ltd. DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC7.html)
CN113784970A (zh) Erk抑制剂及其应用
JP2021530451A5 (cg-RX-API-DMAC7.html)
JP2018135343A5 (cg-RX-API-DMAC7.html)
JP2021528488A5 (cg-RX-API-DMAC7.html)
JP2009536660A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2008536833A5 (cg-RX-API-DMAC7.html)
JP2022137237A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2010506942A5 (cg-RX-API-DMAC7.html)
JP2016521273A5 (cg-RX-API-DMAC7.html)
JP2010523476A5 (cg-RX-API-DMAC7.html)
JP2011504903A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2012508249A5 (cg-RX-API-DMAC7.html)
JP2023531709A5 (cg-RX-API-DMAC7.html)
JP2011519910A5 (cg-RX-API-DMAC7.html)
JP2021530453A5 (cg-RX-API-DMAC7.html)
JP2022512736A5 (cg-RX-API-DMAC7.html)
JP2019519593A5 (cg-RX-API-DMAC7.html)
JP2017505785A5 (cg-RX-API-DMAC7.html)
JP2011509302A5 (cg-RX-API-DMAC7.html)
JP2021510160A5 (cg-RX-API-DMAC7.html)
JP2010527985A5 (cg-RX-API-DMAC7.html)